JW (Cayman) Therapeutics Co. Ltd.
2.37
HKD
-0.17
(-6.88%)
ISIN
KYG5210T1040
CUSIP
G5210T104
Return %
Stock
S&P 500
1Y
-32.86
14.20
3Y
24.74
81.12
5Y
-84.05
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Feng Tian
- Full Time Employees
- 314
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Building B Shanghai SH China 200131
- IPO Date
- Nov 3, 2020
- Website
- jwtherapeutics.com
- Similar Companies
- Business
- JW (Cayman) Therapeutics Co. Ltd operates as an innovative biopharmaceutical firm in the realm of cellular therapeutics, dedicated to the advancement, production, and market introduction of sophisticated cell-based immunotherapies for severe conditions, including various blood cancers, solid tumors, and a growing focus on autoimmune disorders. The company leverages cutting-edge cell-based treatments, primarily CAR-T (chimeric antigen receptor T-cell) interventions, which empower a patient's own immune cells to combat cancerous growths. Its flagship therapeutic, Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 CAR-T therapy, has received approvals for treating adult patients with relapsed or refractory large B-cell lymphoma (LBCL) following multiple lines of systemic therapy, as well as for relapsed or refractory follicular lymphoma (FL). More recently, in early 2024, the National Medical Products Administration (NMPA) accepted a supplemental New Drug Application for Carteyva to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL). Demonstrating its expanded therapeutic potential, Carteyva also secured Breakthrough Therapy Designation in China in January 2025 for its application as a second-line treatment in relapsed or refractory adult LBCL, and is currently undergoing clinical investigation for systemic lupus erythematosus (SLE) after receiving an Investigational New Drug (IND) approval in 2023. The company's extensive development portfolio features JWCAR129, an autologous CAR-T solution targeting multiple myeloma, alongside JWATM204 and JWATM203, both T-cell receptor therapies under evaluation for hepatocellular carcinoma. JW Therapeutics is actively expanding its pipeline to encompass a broader spectrum of hematological cancers, solid tumors, and autoimmune diseases, including dual-targeting CAR-T therapies and innovative approaches to simplify manufacturing. The firm also initiated patient enrollment in March 2024 for an investigator-initiated trial (IIT) of a product candidate targeting MAGE-A4 for various solid tumors. Established in 2016, JW (Cayman) Therapeutics Co. Ltd maintains its primary operational base in Shanghai, People's Republic of China.
Company News
Imugene and JW Therapeutics launch collaborative program to bring CD19 CAR-T innovation to solid tumours